NewEast Biosciences pioneered the research and development of the antibodies for GTPases and mutated Oncogene ten years ago. GTPases involve (1) signal transduction in response to activation of cell surface receptors, including transmembrane receptors such as those mediating taste, smell and vision, (2) protein biosynthesis at the ribosome, (3) regulation of cell differentiation, proliferation, division and movement, (4) translocation of proteins through membranes, (5) transport of vesicles within the cell, and vesicle-mediated secretion and uptake, through GTPase control of vesicle coat assembly. An oncogene is a gene that has the potential to cause cancer.
We offer three unique categories of antibodies, which (1) recognize only the active configuration of GTPase (not the inactive one), (2) mutated Oncogene (not mild type) and (3) have super affinity for cAMP and cGMP (no acetylation required). We have over one thousand peer reviewed articles cited our products.
$349.00
Cat.#: N263046 |
Product Name: Anti-Ubiquitin Conjugating Enzyme E2 D3 Rabbit Monoclonal Antibody |
Synonyms: ubiquitin conjugating enzyme E2D 3; UBC4/5; UBCH5C; E2(17)KB3 |
UNIPROT ID: P61077 |
Background: Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro catalyzes ‘Lys-11’-, as well as ‘Lys-48’-linked polyubiquitination. Cooperates with the E2 CDC34 and the SCF(FBXW11) E3 ligase complex for the polyubiquitination of NFKBIA leading to its subsequent proteasomal degradation. Acts as an initiator E2, priming the phosphorylated NFKBIA target at positions ‘Lys-21’ and/or ‘Lys-22’ with a monoubiquitin. Ubiquitin chain elongation is then performed by CDC34, building ubiquitin chains from the UBE2D3-primed NFKBIA-linked ubiquitin. Acts also as an initiator E2, in conjunction with RNF8, for the priming of PCNA. Monoubiquitination of PCNA, and its subsequent polyubiquitination, are essential events in the operation of the DNA damage tolerance (DDT) pathway that is activated after DNA damage caused by UV or chemical agents during S-phase. Associates with the BRCA1/BARD1 E3 ligase complex to perform ubiquitination at DNA damage sites following ionizing radiation leading to DNA repair. Targets DAPK3 for ubiquitination which influences promyelocytic leukemia protein nuclear body (PML-NB) formation in the nucleus. In conjunction with the MDM2 and TOPORS E3 ligases, functions ubiquitination of p53/TP53. Supports NRDP1-mediated ubiquitination and degradation of ERBB3 and of BRUCE which triggers apoptosis. In conjunction with the CBL E3 ligase, targets EGFR for polyubiquitination at the plasma membrane as well as during its internalization and transport on endosomes. In conjunction with the STUB1 E3 quality control E3 ligase, ubiquitinates unfolded proteins to catalyze their immediate destruction. |
Immunogen: A synthetic peptide of human UBE2D3 |
Applications: WB,IP |
Recommended Dilutions: WB: 1/500-1/1000 IP: 1/20 |
Host Species: Rabbit |
Clonality: Rabbit Monoclonal |
Clone ID: R01-4J4 |
MW: Calculated MW: 17 kDa; Observed MW: 17 kDa |
Isotype: IgG |
Purification: Affinity Purified |
Species Reactivity: Human,Mouse,Rat |
Conjugation: Unconjugated |
Modification: Unmodified |
Constituents: PBS (without Mg2+ and Ca2+), pH 7.3 containing 50% glycerol, 0.5% BSA and 0.02% sodium azide |
Research Areas: Epigenetics and Nuclear Signaling |
Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing |
Western blot analysis of UBE2D3 in K562, rat Brain, C6, 3T3, Hela lysates using Ubiquitin Conjugating Enzyme E2 D3 antibody. |